Arrakis CEO cites ‘cul-de-sacs’ on road to RNA-intercepting cancer drugs Despite some promising data, Michael Gilman says company is switching to muscular dystrophy target

https://www.statnews.com/2024/12/04/arrakis-michael-gilman-cancer-rna-drugs-new-direction/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz-8fo34PURVvZ8B4hwEpncUN0rqqCEy3bisO-3NKevlELrVlhMcx1Qf1MKpo56L_o3T6I1NX4rHYgsDnZOoJBU6gH6DKZA&_hsmi=337057040&utm_content=337057040&utm_source=hs_email